Oncotarget: Paradox breaker BRAF inhibitors in BRAF mutant colorectal cancer
(Impact Journals LLC) Oncotarget Volume 11, Issue 34 features Figure 1, " BRAF inhibitor-induced changes in cell viability, " by Pickles, et which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 25, 2020 Category: Cancer & Oncology Source Type: news

Updated BEACON: Doublet as Good as Triplet in Metastatic CRC Updated BEACON: Doublet as Good as Triplet in Metastatic CRC
The combination of encorafenib and cetuximab is just as effective as the triplet with binimetinib in improving survival and is now the standard of care, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

SU2C hails FDA approval Of Encorafenib + Cetuximab for BRAF V600e-Mutant Metastatic CRC
(Stand Up To Cancer) SU2C welcomed the FDA approval of encorafenib+cetuximab combination for patients with advanced BRAF-mutated CRC. In a Phase 1b/2 clinical trial comparing combinations of encorafenib+cetuximab; and encorafenib+alpelisib+cetuximab in BRAF-mutated CRC, observation by the SU2C-KWF Research Team that patients carrying key mutations in genes associated with the MAP kinase signaling pathway were more responsive supported Breakthrough Therapy Designations for both combination, including encorafenib+cetuximab, for patients with BRAF V600E-mutant metastatic colorectal cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2020 Category: Cancer & Oncology Source Type: news

FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Encorafenib Plus Cetuximab for Metastatic CRC with BRAF V600E Mutation
The FDA approved the combination use of encorafenib and cetuximab for the treatment of adult patients with  BRAFV600E-positive metastatic colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
April 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 8, 2020 Category: Drugs & Pharmacology Source Type: news

Adding Cetuximab to Chemo Curbs Survival in Resectable Colorectal Liver Metastasis Adding Cetuximab to Chemo Curbs Survival in Resectable Colorectal Liver Metastasis
The combination of chemotherapy and the epidermal-growth-factor receptor (EGFR) antibody cetuximab shortens survival compared with chemotherapy alone in certain patients with colorectal cancer, according to an open-label randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 18, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cetuximab + chemotherapy in metastatic CRC: not cost effective in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Grants Priority Review to the sNDA for Encorafenib in Combination with Cetuximab
The combination of encorafenib and cetuximab has shown promise in clinical testing for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Triplet Tx Ups Survival in BRAF V600E - Mutated Colorectal Cancer
Overall survival longer for encorafenib, cetuximab, and binimetinib combo versus standard therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 4, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Conference News, Source Type: news

Triplet Tx Ups Survival in BRAF V600E-Mutated Colorectal Cancer
FRIDAY, Oct. 4, 2019 -- A triplet combination of therapies (encorafenib, cetuximab, and binimetinib) results in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2019 Category: Pharmaceuticals Source Type: news

A systems mechanism for KRAS mutant allele-specific responses to targeted therapy
Cancer treatment decisions are increasingly guided by which specific genes are mutated within each patient’s tumor. For example, agents inhibiting the epidermal growth factor receptor (EGFR) benefit many colorectal cancer (CRC) patients, with the general exception of those whose tumor includes a KRAS mutation. However, among the various KRAS mutations, that which encodes the G13D mutant protein (KRASG13D) behaves differently; for unknown reasons, KRASG13D CRC patients benefit from the EGFR-blocking antibody cetuximab. Controversy surrounds this observation, because it contradicts the well-established mechanisms of EG...
Source: Signal Transduction Knowledge Environment - September 24, 2019 Category: Science Authors: McFall, T., Diedrich, J. K., Mengistu, M., Littlechild, S. L., Paskvan, K. V., Sisk-Hackworth, L., Moresco, J. J., Shaw, A. S., Stites, E. C. Tags: STKE Research Articles Source Type: news

UCLA oncologist Dennis Slamon wins 2019 Lasker Award for clinical medical research
Physician-scientist Dr. Dennis Slamon, professor and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking development of breast cancer drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-positive breast cancer. He shares the award with H. Michael Shepard, an American cancer researcher honored for work he completed at biotechnology company Genentech; and Axel Ullrich, a German cancer researcher from the Max Planck Institute of Biochemistry.The Albert and Mary Lasker Foundation honored Sl...
Source: UCLA Newsroom: Health Sciences - September 10, 2019 Category: Universities & Medical Training Source Type: news

Oral antibiotic use linked to heightened bowel cancer risk
But lower rectal cancer risk, suggesting differences in microbiome activity along the length of the bowel, say researchers Related items fromOnMedica Cetuximab with chemo shrinks more secondaries Statins might not cut colorectal cancer risk after all Invest in workforce to roll out bowel cancer screening, urges former health secretary Bowel cancer screening tests exceed target set in Scotland FOB associated with rise in all-cause mortality (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 21, 2019 Category: UK Health Source Type: news

Immunotherapy could work against bowel cancers resistant to important targeted treatment
(Institute of Cancer Research) Patients with bowel cancer who have stopped responding to a widely used targeted drug could benefit from immunotherapy, a major new study reveals. Scientists found that bowel tumours which had initially responded to cetuximab before developing resistance became more visible to the immune system -- potentially leaving them vulnerable to immunotherapies. A phase II clinical trial has already begun to test the possible benefit of immunotherapy in patients who have stopped responding to cetuximab. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 8, 2019 Category: Cancer & Oncology Source Type: news

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations
(University of Texas M. D. Anderson Cancer Center) The 3-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2019 Category: International Medicine & Public Health Source Type: news

Identifying colorectal cancer subtypes could lead to improved treatment decisions
(University of Southern California - Health Sciences) Identifying a metastatic colorectal cancer patient's Consensus Molecular Subtype could help oncologists determine the most effective course of treatment. For example, Survival for CMS1 patients on bevacizumab was twice that of those on cetuximab, whereas survival for CMS2 patients on cetuximab was six months longer than for bevacizumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news

Woman’s cancer treatment left her with eyelashes 3CM long in a bizarre side effect 
The 45-year-old from Lisbon was being treated for bowel cancer with the drug cetuximab. She found her eyelashes grew rapidly in three weeks, doctors wrote in BMJ Case Reports. (Source: the Mail online | Health)
Source: the Mail online | Health - May 1, 2019 Category: Consumer Health News Source Type: news

Triple drug treatment beats bowel cancer resistance
And researchers say combination therapy could also attack other cancers Related items fromOnMedica Faecal blood testing best to spot cancer and cost-effective Cetuximab with chemo shrinks more secondaries Benefits of aspirin to treat bowel cancer Surgery after radiation therapy effective for rectal cancer Invest in workforce to roll out bowel cancer screening, urges former health secretary (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 25, 2019 Category: UK Health Source Type: news

UCLA ’s Dennis Slamon awarded Sjöberg Prize for pioneering cancer research
Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health& Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future ...
Source: UCLA Newsroom: Health Sciences - February 5, 2019 Category: Universities & Medical Training Source Type: news

Dr. John Mendelsohn, 82, Researcher Who Led Top Cancer Center, Dies
After pioneering a targeted cancer therapy, he oversaw MD Anderson in Houston as it gained a reputation as the nation ’ s top cancer hospital. (Source: NYT Health)
Source: NYT Health - January 18, 2019 Category: Consumer Health News Authors: KATIE THOMAS Tags: Mendelsohn, John Deaths (Obituaries) University of Texas M D Anderson Cancer Center Erbitux (Drug) ImClone Systems Inc Source Type: news

Cisplatin Superior to Cetuximab for HPV + Oropharyngeal Cancer
Toxicity similar in two treatment groups at 24 months, but worse tumor control with cetuximab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 17, 2018 Category: Cancer & Oncology Tags: Oncology, ENT, Pharmacy, Radiology, Journal, Source Type: news

Cisplatin Superior to Cetuximab for HPV+ Oropharyngeal Cancer
MONDAY, Dec. 17, 2018 -- For treatment of human papillomavirus (HPV)-positive low-risk oropharyngeal cancer, cetuximab shows no benefit compared with the standard cisplatin regimen in terms of reduced toxicity and results in worse tumor control,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2018 Category: Pharmaceuticals Source Type: news

Panitumumab cost saving versus  cetuximab
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - December 1, 2018 Category: Drugs & Pharmacology Source Type: news

Head & Neck Cancer: Mixed Results with Intensified Therapy
(MedPage Today) -- Concurrent chemo with cetuximab-RT improves PFS but not induction (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 7, 2018 Category: Primary Care Source Type: news

No De-escalation of Therapy for HPV+ Throat Cancer No De-escalation of Therapy for HPV+ Throat Cancer
De-escalating therapy by using cetuximab with radiotherapy did not improve side effects and, more importantly, had worse survival compared with chemoradiotherapy for patients with good prognosis HPV+ throat cancers.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 26, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

RTOG 1016: Cisplatin Still Standard for HPV-Related Oral Cancer RTOG 1016: Cisplatin Still Standard for HPV-Related Oral Cancer
Cisplatin plus radiation therapy was superior to cetuximab/radiation therapy for all endpoints, but toxicity burden is much higherMedscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASTRO: Oropharynx CA Survival Rates Worse With RT/Cetuximab
FRIDAY, Oct. 26, 2018 -- For patients with locoregionally advanced human papillomavirus (HPV)-related oropharynx cancer, radiation/cetuximab results in inferior overall and progression-free survival versus radiation/cisplatin, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2018 Category: Pharmaceuticals Source Type: news

Cetuximab Fails Twice vs Cisplatin for HPV-Related Oral Ca
(MedPage Today) -- Cetuximab resulted in more patient deaths across U.S., German studies (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 23, 2018 Category: Hematology Source Type: news

Patients with HPV-positive oropharynx cancer should receive chemoradiation
(European Society for Medical Oncology) Patients with human papilloma virus (HPV)-positive throat cancer should receive chemoradiotherapy rather than cetuximab with radiotherapy, according to late-breaking research reported at the ESMO 2018 Congress in Munich. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 22, 2018 Category: International Medicine & Public Health Source Type: news

No Change in Standard of Care for HPV+ Oropharyngeal Cancer No Change in Standard of Care for HPV+ Oropharyngeal Cancer
Interim results of a large phase III trial showed that patients treated with a cetuximab regimen has worse survival than those treated with cisplatin plus radiation therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 20, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cetuximab Failure in HPV+ Head and Neck Cancer
(MedPage Today) -- Inferior survival when paired with radiation therapy (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 16, 2018 Category: American Health Source Type: news

Chemicals in green vegetables show to prevent bowel cancer
Diets high in indole-3-carbinol protect stomach cells from chaotic division Related items fromOnMedica FOB associated with rise in all-cause mortality Colorectal cancer risk link to ‘inflammatory’ foods Taking aspirin with a PPI reduces risk of oesophageal cancer Cetuximab with chemo shrinks more secondaries Overweight teens more likely to have severe liver disease later (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 15, 2018 Category: UK Health Source Type: news

Study: Cetuximab, radiation inferior to standard HPV throat cancer treatment
Treating HPV-positive throat cancer with cetuximab and radiation had worse overall and progression-free survival compared with radiation and cisplatin. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 14, 2018 Category: Consumer Health News Source Type: news

Cetuximab with radiation found to be inferior to standard treatment in HPV-positive oropharyngeal cancer
. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 14, 2018 Category: American Health Source Type: news

Cetuximab+RT found to be inferior to standard treatment in HPV+ oropharyngeal cancer
(NIH/National Cancer Institute) An interim analysis of data from a randomized clinical trial of patients with human papillomavirus (HPV)-positive oropharyngeal cancer found that treatment with radiation therapy and cetuximab is associated with worse overall and progression-free survival compared to the current standard treatment with radiation and cisplatin. The trial was designed to see if cetuximab with radiation would be less toxic than cisplatin with radiation without compromising survival for patients with the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 14, 2018 Category: Cancer & Oncology Source Type: news

Clinical trial suggests new direction for heavy-smoking head and neck cancer patients
(University of Colorado Anschutz Medical Campus) Phase I results of olaparib with cetuximab and radiation led to 72 percent 2-year survival in 16 patients on trial, compared with an expected 2-year survival rate of about 55 percent for standard-of-care treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 14, 2018 Category: International Medicine & Public Health Source Type: news

Can New Algorithm Shed Light on Treatment Resistance in Head and Neck Cancer?
The CoGAPS gene activity algorithm may elucidate molecular changes that occur as H&N tumors acquire resistance to cetuximab, says a Johns Hopkins team. (Source: CancerNetwork)
Source: CancerNetwork - July 30, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Pazopanib/Cetuximab Combo Promising in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma
A Washington University School of Medicine team ’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

A Better Regimen for Head and Neck Cancer?
(MedPage Today) -- Study backs combo of chemotherapy, cetuximab, and radiotherapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2018 Category: Hematology Source Type: news

Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC
John SchieszerJun 6, 2018A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab –based therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Cetuximab and panitumumab cost  effective for mCRC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

A specific new ELISA method for analyzing cetuximab
This study describes the development and full validation of a new enzyme-linked immunosorbent assay (ELISA) with high sensitivity and selectivity for bioanalysis of CET. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2018 Category: Cancer & Oncology Source Type: news

Therapy Order Affects Survival in Metastatic CRC
(MedPage Today) -- Big gain with regorafenib before cetuximab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 21, 2018 Category: Primary Care Source Type: news

Cetuximab Paired With Dye Can Image Glioblastoma Cetuximab Paired With Dye Can Image Glioblastoma
The antibody cetuximab paired with a fluorescent dye can image glioblastoma during brain surgery, a pilot study showed.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2017 Category: Consumer Health News Tags: General Surgery News Source Type: news

Vanderbilt researchers find novel mechanism of resistance to anti-cancer drugs
(Vanderbilt University Medical Center) Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported Oct. 16 in Nature Medicine, suggest a strategy for overcoming this resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 16, 2017 Category: Cancer & Oncology Source Type: news

NICE recommends Merck ’s erbitux to treat R/M SCCHN in oral cavity
The UK National Institute for Health and Care Excellence (NICE) has recommended the routine use of Merck ’s erbitux (cetuximab), in combination with platinum-based chemotherapy, to treat recurrent and / or metastatic (R/M) squamous cell carcinoma of t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news

Results of NRG-RTOG 0436 highlight need for biomarkers in treatment of esophageal cancer
(NRG Oncology) NRG-RTOG 0436 has determined that adding an epidermal growth factor receptor (EGFR) inhibitor to a chemo-radiation regimen does not improve overall survival for patients with locally advanced esophageal cancer treated in a non-operative manner. These results are reported in 'Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients with Esophageal Cancer -- The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial,' which was recently published in the Journal of the American Medical Association Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2017 Category: International Medicine & Public Health Source Type: news

Erbitux (Cetuximab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 21, 2017 Category: Drugs & Pharmacology Source Type: news

Adding Cetuximab in Esophageal Cancer Fails to Improve Survival
Use of the EGFR inhibitor cetuximab with chemoradiation did not improve survival in patients with esophageal carcinoma compared with chemoradiation alone, according to the results of the phase III RTOG 0436 trial. (Source: CancerNetwork)
Source: CancerNetwork - July 13, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Esophageal Cancer Gastrointestinal Cancer News Source Type: news